US4427668A
Expired / Lapsed
US
⏱️ 0.0 years remaining
26-Hydroxycholesterol and derivatives and analogs thereof in regulation of cholesterol accumulation in body tissue
Assignee: New York University
•
Filing: 1982-04-01
•
Granted: 1984-01-24
•
Expires: 2002-04-01
Abstract
Abstract Use of 26-hydroxycholesterol for reducing cholesterol synthesis and/or accumulation in body tissues.
Inventors
- 👤 Norman B. Javitt
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 23:07
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/575; A61P; A61P25/00; A61P25/02; A61P3/00; A61P3/06; A61P43/00
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
38 words
A process for reducing the rate of cholesterol synthesis by a human which comprises administering to said human a cholesterol synthesis rate-reducing amount of 26-hydroxycholesterol or a fatty acid ester, a sulfate, a carbonate of a glucuronide thereof.
Claim 2
Dependent Claim
38 words
A process for reducing the rate of cholesterol synthesis by a human which comprises administering to said human a cholesterol synthesis rate-reducing amount of 26-hydroxycholesterol or a fatty acid ester, a sulfate, a carbonate of a glucuronide thereof.
Claim 3
Dependent Claim
50 words
A process for reducing the rate of cholesterol accumulation in body tissues which comprises administering to an individual 26-hydroxycholesterol or a fatty acid ester, a sulfate, a carbonate or a glucuronide thereof, in an amount sufficient to reduce the rate of cholesterol accumulation in the body tissues of said individual.
Claim 4
Dependent Claim
50 words
A process for reducing the rate of cholesterol accumulation in body tissues which comprises administering to an individual 26-hydroxycholesterol or a fatty acid ester, a sulfate, a carbonate or a glucuronide thereof, in an amount sufficient to reduce the rate of cholesterol accumulation in the body tissues of said individual.
Claim 5
Dependent Claim
44 words
A process for treating atherosclerosis which comprises administering to an individual having atherosclerosis 26-hydroxycholesterol or a fatty acid ester, a sulfate, a carbonate or a glucuronide thereof, in an amount sufficient to reduce the rate of cholesterol accumulation along the arteries of said individual.
Claim 6
Dependent Claim
44 words
A process for treating atherosclerosis which comprises administering to an individual having atherosclerosis 26-hydroxycholesterol or a fatty acid ester, a sulfate, a carbonate or a glucuronide thereof, in an amount sufficient to reduce the rate of cholesterol accumulation along the arteries of said individual.
Claim 7
Dependent Claim
82 words
A process for preventing abnormally high cholesterol accumulation in body tissues which comprises determining the level of 26-hydroxycholesterol in the serum or other biological fluid of an individual, comparing that level with the normal range for 26-hydroxycholesterol in serum or other biological fluid and then administering 26-hydroxycholesterol or a fatty acid ester, a sulfate, a carbonate or a glucuronide thereof to said individual in an amount sufficient to raise the 26-hydroxycholesterol level of said individual to at least within said normal range.
Claim 8
Dependent Claim
82 words
A process for preventing abnormally high cholesterol accumulation in body tissues which comprises determining the level of 26-hydroxycholesterol in the serum or other biological fluid of an individual, comparing that level with the normal range for 26-hydroxycholesterol in serum or other biological fluid and then administering 26-hydroxycholesterol or a fatty acid ester, a sulfate, a carbonate or a glucuronide thereof to said individual in an amount sufficient to raise the 26-hydroxycholesterol level of said individual to at least within said normal range.
Claim 9
Dependent Claim
15 words
The process of claim 4 wherein the level of 26-hydroxycholesterol is determined in blood serum.
Claim 10
Dependent Claim
19 words
The process of any of claims 1 to 5 wherein 26-hydroxycholesterol or a fatty acid ester thereof is administered.
Claim 11
Dependent Claim
19 words
The process of claim 6 wherein the 26-hydroxycholesterol is administered in an amount of about 5 to 25 mg/kg.
Claim 12
Dependent Claim
11 words
The process of claim 6 wherien the ester is a sulfate.
Claim 13
Dependent Claim
31 words
The process of claim 1 wherein the 26-hydroxycholesterol or fatty acid ester, sulfate, carbonate or glucuronide thereof is administered in an amount, based on 26-hydroxycholesterol, of about 5 to 25 mg/kg.
Claim 14
Dependent Claim
31 words
The process of claim 2 wherein the 26-hydroxycholesterol or fatty acid ester, sulfate, carbonate or glucuronide thereof is administered in an amount, based on 26-hydroxycholesterol, of about 5 to 25 mg/kg.
Claim 15
Dependent Claim
31 words
The process of claim 3 wherein the 26-hydroxycholesterol or fatty acid ester, sulfate, carbonate or glucuronide thereof is administered in an amount, based on 26-hydroxycholesterol, of about 5 to 25 mg/kg.
Claim 16
Dependent Claim
31 words
The process of claim 4 wherein the 26-hydroxycholesterol or fatty acid ester, sulfate, carbonate or glucuronide thereof is administered in an amount, based on 26-hydroxycholesterol, of about 5 to 25 mg/kg.
Claim 17
Dependent Claim
32 words
The process of claim 5 wherein the 26 -hydroxycholesterol or fatty acid ester, sulfate, carbonate or glucuronide thereof is administered in an amount, based on 26-hydroxycholesterol, of about 5 to 25 mg/kg.
Claim 18
Independent Claim
44 words
A method for predicting an individual's predisposition toward tissue cholesterol accumulation which comprises determining the level of 26-hydroxycholesterol in the serum or other biological fluid of said individual and comparing that level with the normal range for 26-hydroxycholesterol in serum or other biological fluid.
Claim 19
Independent Claim
44 words
A method for predicting an individual's predisposition toward tissue cholesterol accumulation which comprises determining the level of 26-hydroxycholesterol in the serum or other biological fluid of said individual and comparing that level with the normal range for 26-hydroxycholesterol in serum or other biological fluid.
Claim 20
Dependent Claim
15 words
The process of claim 14 wherein the level of 26-hydroxycholesterol is determined in blood serum.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-01-23 | 1987-07-25 | 1988-01-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-01-23 | 1991-07-25 | 1992-01-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-01-23 | 1995-07-25 | 1996-01-24 | $7700.00 | Window Closed / Lapsed |